Cooley advised F1 Oncology affiliate Exuma Biotechnology on its acquisition of rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in China….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
